Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
VST Industries Limited - Trading Window

2018-07-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509966 VSTIND

4
In Pictures: A look at the richest Indians in the world

2018-04-15 moneycontrol
The number of billionaires in India has increased by 19 to 121 according to the latest annual Forbes’ Billionaires List. Indians now account for the third largest pool of billionaires in the world after the Americans and the Chinese.
500325 KMBKY RELIANCE HCTHY 530005 509966 RIGD HCLTECH KOTAKBANK VSTIND 532281 500247 INDIACEM RLNIY

0
VST Industries Limited - Updates

2018-04-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509966 VSTIND

0
Reliance Industrial, VST Ind results

2018-04-11 thehindubusinessline
Thursday will see two companies - Reliance Industrial Infrastructure and VST Industries, declaring their financial results for the quarter as well as the year ended March 2018.
509966 VSTIND RIIL 523445

0
VST Industries Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509966 VSTIND

0
VST Industries Limited - Trading Window

2018-03-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509966 VSTIND

34
Market Live: Nifty extends losses ahead of FO expiry, Sensex loses 200 pts

2018-03-28 moneycontrol
3:06 pm Persistent's FY19 Outlook: Persistent Systems clarifed that in terms of the outlook for FY 2018-19, it expects a steady growth in both revenue streams - service revenues and IP revenues.
BALKRISIND 513262 500325 ASHIANA FSL RELIANCE IDBI 539336 532859 MDCO GSPL 532612 533179 531431 509966 532121 RIGD GSK BJJQY 500676 502355 RLNIY 500034 SBAZ 532809 500116 523716 INDOCO GSKCONS HGS 532702 CPICQ 532843 GSK HINDUJAVEN GUJGAS BAJFINANCE FORTIS 500189 VSTIND DENABANK SSWL SHAKTIPUMP PERSISTENT

27
Market Live: Sensex, Nifty Bank fall over 150 pts; Alkem Labs, Persistent dip 10%

2018-03-28 moneycontrol
2:01 pm NLC Deal Called-Off: Damodar Valley Corporation has called off a deal with NLC India for acquisition of DVC's power station through JV.
BALKRISIND 513262 ASHIANA IDBI 532859 MDCO 532612 533179 531431 509966 532121 BJJQY 502355 500034 SBAZ 500116 523716 INDOCO HGS 532843 HINDUJAVEN BAJFINANCE FORTIS 500189 VSTIND DENABANK SSWL SHAKTIPUMP PERSISTENT

27
Market Live: Sensex off day#39;s low, Nifty weak ahed of FO expiry; Europe down

2018-03-28 moneycontrol
12:42 pm Buzzing: Shares of Kakatiya Cements added 9 percent intraday as Central Pollution Control Board (CPCB) revokes closure order on company’s cement plant.
BALKRISIND 513262 ASHIANA IDBI MDCO 532612 533179 531431 509966 532121 BJJQY 502355 500034 SBAZ 500116 523716 INDOCO 532843 HINDUJAVEN BAJFINANCE FORTIS 500189 VSTIND DENABANK SSWL SHAKTIPUMP PERSISTENT

27
Market Live: Sensex, Nifty under pressure; PSU banks, autos, IT rebound

2018-03-28 moneycontrol
12:00 am Order Win: The construction arm of Larsen & Toubro has won orders worth Rs 1,521 crore.
BALKRISIND 513262 500116 ASHIANA 523716 IDBI INDOCO MDCO 532612 533179 532843 509966 532121 BAJFINANCE FORTIS VSTIND BJJQY DENABANK 502355 SSWL PERSISTENT 500034 SBAZ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...